about us


Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaboration with partners, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease.


Pulmatrix Profile – Health and Science Report


Pulmatrix’s iSPERSE™: An Engineered Solution to Effectively Treat Respiratory Diseases



Recent News
AAA8 – 2018 – Efficacy of PUR1900, An Inhaled Antifungal Therapy, in a Guinea Pig Model of Invasive Pulmonary Aspergillosis / PDF
May 16, 2019

Pulmatrix, Inc. (NASDAQ: PULM) announces today that Dr. Robert Clarke has stepped down as Chief Executive Officer. Ted Raad will immediately transition from his current role as Chief Business...

May 15, 2019

Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone in the first quarter with the FDA providing approval to begin our planned Pulmazole Phase 2...

Apr 15, 2019

Pulmatrix, Inc. (NASDAQ: PULM; hereafter referred to as "Pulmatrix"), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in...

Monday, January 11, 2016
5:30pm - 6:00pm EST
Wednesday, March 9, 2016
11:20am - 11:50am EST

© 2015 Pulmatrix, Inc. All Rights Reservedhome   about pulmatrix   platform   pipeline   investors   careers   contact   site design